Interview with Ala Ciobanu, General Manager, Roche Ukraine
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
Address: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Welwyn Garden City, Hertfordshire, AL7 1TW, United Kingdom
Tel: +44 (0)1707 366000
Web: http://www.roche.co.uk/portal/uk
Headquartered in Basel, Switzerland, Roche employs around 2,000 people in the UK in pharmaceuticals, based at Welwyn Garden City in Hertfordshire, and diagnostics, based at Burgess Hill in East Sussex.
The UK pharmaceuticals headquarters at Welwyn Garden City in Hertfordshire is home to Roche’ global pharmaceutical product development team, its pharmaceuticals sales and marketing teams and corporate functions.
The purpose built facility that opened in 2005 at Shire Park in Welwyn Garden City, reflects and supports the continued success of Roche’s pharmaceutical business.
In 2006 Roche’ UK diagnostics sales and marketing team relocated to a new purpose-built facility in Burgess Hill, East Sussex.
As the UK’s leading in-vitro diagnostics company, Roche has a dynamic UK sales and marketing team who consistently deliver growth above the market rate.
As one of the major pharmaceutical and diagnostic companies in the UK, Roche develops and provides an innovative range of products and services that help healthcare professionals improve the health and well-being of the UK population.
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
Karen Osborn, CEO of the International Glaucoma Association, explains the role of the charity, detailing its threefold purpose of funding research, raising awareness and helping patients live with the disease.…
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
See our Cookie Privacy Policy Here
